MDLN vs. PEN: Medline vs. Penumbra Stock Comparison

Company Profile

Medline (MDLN) and Penumbra (PEN) both belong to the Health Care Equipment & Supplies industry, though MDLN is classified under Health Care Supplies while PEN falls under Health Care Equipment.

Penumbra (PEN) has been public since September 18, 2015 with a meaningfully longer listed history, while Medline (MDLN) only listed on December 17, 2025 — long-window metrics on the MDLN side should be interpreted with caution.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Medline (MDLN) reports a negative beta of -0.93, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. Penumbra (PEN) has a non-negative beta of 0.68.

Risk-Adjusted Performance

Risk-Return Positioning

Both MDLN and PEN need 1-year volatility and 1-year return to plot risk-return positioning.

Risk-Adjusted Metrics

Profitability

Both Medline (MDLN) at 4.85% and Penumbra (PEN) at 10.67% land near their industries’ usual ROE ranges, so capital efficiency looks broadly in line with peers on both sides.

Penumbra (PEN) at 10.06% retains a top-quartile share of revenue as profit, ahead of Medline (MDLN) at 1.85%, which keeps about the industry-typical share.

Both Medline (MDLN) at 5.22% and Penumbra (PEN) at 12.37% run core operations about as efficiently as their industries’ norm — neither stands out on operating profitability.

Profitability Metrics

Growth

Only one side can be read here: Penumbra (PEN) reports revenue growth of 17.50%, ranked against its industry; Medline (MDLN) has no revenue growth figure this period.

Both Medline (MDLN) at 117.38% and Penumbra (PEN) at 1,155.56% grew per-share earnings faster than their entire industry benchmark ranges for EPS growth — a strong showing on both sides, though a depressed base year can exaggerate the percentage, so the level of earnings matters too.

Growth Metrics

Financial Strength

Both Medline (MDLN) at 4.04 and Penumbra (PEN) at 5.89 post current ratio above their industries’ typical mid-ranges — short-term liquidity appears comfortable, though unusually high readings can point to idle current assets.

Penumbra (PEN) at 0.13 keeps leverage in the lower industry quartile, while Medline (MDLN) at 0.65 runs a more typical debt-to-equity mix.

Financial Strength Metrics

Dividends

Neither Medline (MDLN) nor Penumbra (PEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Medline (MDLN) nor Penumbra (PEN) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

Both look expensive on trailing earnings: Penumbra (PEN) at 80.41 sits in the richer P/E ratio quartile, and Medline (MDLN) at 90.09 is richer still, above its industry range.

Medline (MDLN) at 1.70 is priced about in line with its industry on P/S ratio, while Penumbra (PEN) at 8.06 sits in the pricier quartile — PEN costs more per dollar of sales.

Medline (MDLN) at 2.95 is valued about in line with its industry on P/B ratio, while Penumbra (PEN) at 7.95 carries an above-peer premium to book — PEN is pricier on assets.

Valuation Metrics